Cardio-oncology: Shared genetic, metabolic, and pharmacologic mechanism

Y Zhao, H Jia, X Hua, T An, J Song - Current Cardiology Reports, 2023 - Springer
Abstract Purpose of Review The article aims to investigate the complex relationship between
cancer and cardiovascular disease (CVD), with a focus on the effects of cancer treatment on …

Cell death regulation in myocardial toxicity induced by antineoplastic drugs

X Yu, Y Yang, T Chen, Y Wang, T Guo, Y Liu… - Frontiers in Cell and …, 2023 - frontiersin.org
Homeostatic regulation of cardiomyocytes plays a critical role in maintaining normal
physiological activity of cardiac tissue. Severe cardiotoxicity can lead to heart disease …

Clinical trial in a dish: using patient-derived induced pluripotent stem cells to identify risks of drug-induced cardiotoxicity

CK Lam, JC Wu - Arteriosclerosis, thrombosis, and vascular biology, 2021 - Am Heart Assoc
Drug-induced cardiotoxicity is a significant clinical issue, with many drugs in the market
being labeled with warnings on cardiovascular adverse effects. Treatments are often …

Human iPSCs and genome editing technologies for precision cardiovascular tissue engineering

EKN Gähwiler, SE Motta, M Martin… - Frontiers in Cell and …, 2021 - frontiersin.org
Induced pluripotent stem cells (iPSCs) originate from the reprogramming of adult somatic
cells using four Yamanaka transcription factors. Since their discovery, the stem cell (SC) field …

Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity

M Kumar, C Thangavel, RC Becker, S Sadayappan - Cancers, 2020 - mdpi.com
Simple Summary The application of immunotherapies to treat cancer patients has
significantly improved over the last two decades and extended many patients' life spans …

Building multi-dimensional induced pluripotent stem cells-based model platforms to assess cardiotoxicity in cancer therapies

D Thomas, S Shenoy, N Sayed - Frontiers in Pharmacology, 2021 - frontiersin.org
Cardiovascular disease (CVD) complications have contributed significantly toward poor
survival of cancer patients worldwide. These complications that result in myocardial and …

Drug development and the use of induced pluripotent stem cell-derived cardiomyocytes for disease modeling and drug toxicity screening

P Ovics, D Regev, P Baskin, M Davidor… - International Journal of …, 2020 - mdpi.com
Over the years, numerous groups have employed human induced pluripotent stem cell-
derived cardiomyocytes (iPSC-CMs) as a superb human-compatible model for investigating …

Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity

JM Miller, MH Meki, Q Ou, SA George, A Gams… - Toxicology and applied …, 2020 - Elsevier
The limited availability of human heart tissue and its complex cell composition are major
limiting factors for the reliable testing of drug efficacy and toxicity. Recently, we developed …

iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity

TYT Lee, JG Coles, JT Maynes - Frontiers in Pharmacology, 2024 - frontiersin.org
Many challenges remain in the preclinical evaluation, adjudication, and prioritization of
novel compounds in therapeutic discovery pipelines. These obstacles are evident by the …

Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity

S Liu, C Fang, C Zhong, J Li, Q Xiao - Cell Biology and Toxicology, 2023 - Springer
Cardiovascular disease (CVD) caused by anti-cancer drug-induced cardiotoxicity is now the
second leading cause of mortality among cancer survivors. It is necessary to establish …